CurrentNeighborhood Health Plan of Rhode IslandPolicy N/A

Freestyle Libre and Dexcom Continuous Glucose Monitoring (CGM) Coverage Criteria

Coverage and utilization rules for Freestyle Libre and Dexcom continuous glucose monitoring (CGM) readers, transmitters, and sensors for members with diabetes; defines required medical information, quantity limits, coverage duration, and a coding-based therapy requirement.

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyFreestyle Libre and Dexcom Continuous Glucose Monitoring (CGM) Coverage Criteria

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionDocument that the member is currently using non-basal insulin OR has Type 1 or Type 2 diabetes and is at high risk of hypoglycemia, recurrent hypoglycemia, or hypoglycemia unawareness.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

12 monthscoverage duration

1 / 365dreader replacement limit

2 / 28dLibre sensor limit

90dtransmitter interval

180 dayscoding lookback

Coverage Criteria

Medical necessity criteria (general)

Covered when ALL of the following are met:

Primary coverage conditions: Member is currently utilizing non-basal insulin for the treatment of diabetes OR (member has Type 1 or Type 2 Diabetes Mellitus AND the member is at high risk of hypoglycemia, recurring episodes of hypoglycemia, or hypoglycemia unawareness)

Either branch satisfies requirement

Quantity limits and duration

Covered supplies and limits

Quantity limits: Freestyle Libre / Freestyle Libre 2 / Freestyle Libre 3 Reader: 1 reader per 365 days; Freestyle Libre / Freestyle Libre 2 / Freestyle Libre 3 Sensors: 2 sensors per 28 days; Dexcom Receiver: 1 receiver per 365 days; Dexcom Transmitter: 1 box per 90 days

Coverage duration: 12 months

Coding logic for therapy

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyFreestyle Libre and Dexcom Continuous Glucose Monitoring (CGM) Coverage Criteria

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionDocument that the member is currently using non-basal insulin OR has Type 1 or Type 2 diabetes and is at high risk of hypoglycemia, recurrent hypoglycemia, or hypoglycemia unawareness.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coding-based therapy verification

Coding lookback: At least one paid claim within the last 180 days for non-basal insulin (e.g., regular, lispro, aspart)>=1 claim in 180 days

Used to validate ongoing non-basal insulin use

Neighborhood Health Plan of Rhode Island does not provide coverage for therapies used for investigational purposes. Investigational use is defined as use at a dose or for a condition that is not recognized as a medically accepted indication in standard reference compendia (for example, AHFS-DI, Thomson Micromedex DrugDex, Clinical Pharmacology, Wolters Kluwer Lexi-Drugs) or supported by peer-reviewed published medical literature. Therapies meeting this investigational definition are excluded from coverage.

Devices or drug uses considered investigational per the payer definition are not covered. Specifically, coverage is limited to indications and doses recognized as medically accepted in standard compendia or supported by peer-reviewed literature; uses outside those accepted indications are considered investigational and are excluded from coverage.

Coding and Claims Logic

Coding logic for therapy verificationmixed

affected codes

Coding logic references claims for non-basal insulin (examples: regular, lispro, aspart) within last 180 days to support coverage.

Coding lookback window for non-basal insulin

Lookback window>= 1 paid claim for non-basal insulin within the last 180 days

Examples of non-basal insulin citedregular insulin, lispro, aspart

PurposeUsed by coding logic to validate ongoing non-basal insulin therapy for coverage

Provider Actions and Documentation Requirements

Documentation Required

Medical necessity and coding lookback

Coverage requires documentation of the required medical information. Provider must document current non-basal insulin use OR diabetes type and clinical justification (e.g., member has Type 1 or Type 2 diabetes and is at high risk of hypoglycemia, has recurrent hypoglycemia, or hypoglycemia unawareness). Coding logic will verify at least one paid claim for non-basal insulin within the last 180 days.

Document: current non-basal insulin use (e.g., regular, lispro, aspart) OR diabetes type with clinical justification for CGM/reader/sensor coverage.
Lookback: at least one claim for non-basal insulin within the last 180 days is required by coding logic.

Note

Provider note

Provider-facing highlight: ensure all required fields and supporting clinical notes are present on the request to avoid processing delays.

Documentation Required

Required medical information

Provider must document either current non-basal insulin use OR the member's diabetes type with clinical justification (high risk of hypoglycemia, recurrent hypoglycemia, or hypoglycemia unawareness) when requesting Freestyle Libre or Dexcom devices.

Acceptable documentation: medication list showing non-basal insulin use OR clinical notes describing diabetes type and hypoglycemia risk/unawareness.

Billing Rule

Supply documentation and replacement process

Request supplies consistent with the policy quantity limits and manufacturer guidance. Use the information on the Freestyle Libre sensor box for replacement sensor details and contact the manufacturer if the sensor falls off to obtain a replacement per manufacturer process.

Freestyle Libre/Freestyle Libre 2/3 Reader: 1 reader per 365 days.
Freestyle Libre/Freestyle Libre 2/3 Sensors: 2 sensors per 28 days.
Dexcom Receiver: 1 receiver per 365 days.
Dexcom Transmitter: 1 box per 90 days.
If a sensor dislodges/falls off, contact the manufacturer for replacement per their process.

Denial Risk

Missing required medical information

Failure to provide the required medical information or supporting documentation may result in denial of the request. Ensure the clinical rationale and medication claims are included with the submission.

Missing: absence of documentation of non-basal insulin use and no documented clinical justification for diabetes type/hypoglycemia risk.
Consequence: claim or prior authorization may be denied if required information is not provided.

Background

Continuous glucose monitoring (CGM) systems such as the Freestyle Libre and Dexcom products provide interstitial glucose measurements and alerts to help manage diabetes. These devices can be particularly useful for members who are at high risk of hypoglycemia or who are using non-basal (short-acting or prandial) insulin, by providing ongoing glucose trend data and hypoglycemia warnings to reduce hypoglycemic events.

Definitions

High hypoglycemia risk / hypoglycemia unawareness

DefinitionHigh risk of hypoglycemia, recurring episodes of hypoglycemia, or hypoglycemia unawareness as used in coverage criteria

Context for coverageApplies when member has Type 1 or Type 2 Diabetes Mellitus AND is at high risk of hypoglycemia, recurrent hypoglycemia, or has hypoglycemia unawareness

Alternative pathwaySatisfies coverage requirement when member is at high hypoglycemia risk even if not currently using non-basal insulin